BioCardia Statistics
Total Valuation
BioCardia has a market cap or net worth of $10.09 million. The enterprise value is $6.57 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, after market close.
Earnings Date | Nov 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
BioCardia has 4.58 million shares outstanding. The number of shares has increased by 47.00% in one year.
Current Share Class | 4.58M |
Shares Outstanding | 4.58M |
Shares Change (YoY) | +47.00% |
Shares Change (QoQ) | +50.63% |
Owned by Insiders (%) | 18.38% |
Owned by Institutions (%) | 2.30% |
Float | 3.71M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 63.34 |
Forward PS | 505.62 |
PB Ratio | 3.75 |
P/TBV Ratio | 3.75 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 92.50 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.78, with a Debt / Equity ratio of 0.38.
Current Ratio | 1.78 |
Quick Ratio | 1.74 |
Debt / Equity | 0.38 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -737.89% and return on invested capital (ROIC) is -213.96%.
Return on Equity (ROE) | -737.89% |
Return on Assets (ROA) | -96.91% |
Return on Capital (ROIC) | -213.96% |
Revenue Per Employee | $3,550 |
Profits Per Employee | -$386,100 |
Employee Count | 20 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.39% in the last 52 weeks. The beta is 1.27, so BioCardia's price volatility has been higher than the market average.
Beta (5Y) | 1.27 |
52-Week Price Change | -77.39% |
50-Day Moving Average | 2.47 |
200-Day Moving Average | 3.98 |
Relative Strength Index (RSI) | 48.78 |
Average Volume (20 Days) | 48,282 |
Short Selling Information
The latest short interest is 109,483, so 2.39% of the outstanding shares have been sold short.
Short Interest | 109,483 |
Short Previous Month | 86,275 |
Short % of Shares Out | 2.39% |
Short % of Float | 2.95% |
Short Ratio (days to cover) | 1.41 |
Income Statement
In the last 12 months, BioCardia had revenue of $71,000 and -$7.72 million in losses. Loss per share was -$3.92.
Revenue | 71,000 |
Gross Profit | -4.06M |
Operating Income | -7.76M |
Pretax Income | -10.34M |
Net Income | -7.72M |
EBITDA | -7.69M |
EBIT | -7.76M |
Loss Per Share | -$3.92 |
Full Income Statement Balance Sheet
The company has $4.93 million in cash and $1.05 million in debt, giving a net cash position of $3.89 million or $0.85 per share.
Cash & Cash Equivalents | 4.93M |
Total Debt | 1.05M |
Net Cash | 3.89M |
Net Cash Per Share | $0.85 |
Equity (Book Value) | 2.75M |
Book Value Per Share | 0.61 |
Working Capital | 2.22M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$7.30 million and capital expenditures -$5,000, giving a free cash flow of -$7.31 million.
Operating Cash Flow | -7.30M |
Capital Expenditures | -5,000 |
Free Cash Flow | -7.31M |
FCF Per Share | -$1.59 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | -10,935.21% |
Pretax Margin | -10,876.06% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -1,911.54% |
Dividends & Yields
BioCardia does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -47.00% |
Shareholder Yield | -47.00% |
Earnings Yield | -74.86% |
FCF Yield | -70.86% |
Analyst Forecast
The average price target for BioCardia is $25.00, which is 1,036.36% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $25.00 |
Price Target Difference | 1,036.36% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on May 30, 2024. It was a reverse split with a ratio of 0.0666667:1.
Last Split Date | May 30, 2024 |
Split Type | Reverse |
Split Ratio | 0.0666667:1 |
Scores
BioCardia has an Altman Z-Score of -37.2 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -37.2 |
Piotroski F-Score | 2 |